Alnylam updated ‘checks nearly all the boxes,’ says Barclays

Barclays says the update from Alnylam Pharmaceuticals “checks nearly all the boxes” for vutrisiran and supports at least comparable or likely better, clinical profile versus stabilizers. Regardless of the wide spectrum of key opinion leader feedback on the data, all estimated 20%-50% usage of silencers in first-line and vast majority in second-line therapy post tafamidis, the analyst tells investors in a research note. The firm keeps an Overweight rating on Alnylam with a $295 price target.